UCB and Novartis to expand cooperation in Germany

UCB further strengthens its second largest market, Germany

24-Aug-2009 - Germany

UCB and Novartis announced that they entered into a licensing agreement for cardiovascular and diabetes products in Germany. Under the agreement, UCB has extended commercial rights for the German market to the cardiovascular medication Provas® (valsartan) beyond 2011 and has licensed in commercial rights for two line extensions: Dafiro® (Valsartan and amlodipine) and Dafiro HCT® (valsartan, amlodipine and HCT). Dafiro HCT® is the first drug for the treatment of hypertension with a combination of three compounds in about 20 years. In addition, UCB will co-commercialize the two new oral anti-diabetics Jalra® and Icandra® (vildagliptin and vildagliptin + metformin).

"With this agreement we are building on our strengths in Germany, our excellent position in the Internal Medicine segment," said Willy Cnops, Vice President UCB and Managing Director Germany. "We are extending our cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options to date in line with UCB's ambitions to offer the best medicines to our patients."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances